VC fund profile · evidence-aware directory data
Sofinnova Crossover I (€445M final close, 2021) stages, portfolio and investment profile
Predecessor late-stage healthcare crossover vehicle of Sofinnova Partners. The GP announced a €445M FINAL close on March 3, 2021, after an earlier €275M initial close in April 2018. Investments included later-stage European biopharma and medtech companies seeking scale-up capital. The fund's notable GP-cited companies include Amolyt Pharma, Abivax, LimFlow and Calliditas. No 2026 incremental raise is implied.
Keep track of Sofinnova Crossover I (€445M final close, 2021)
Save this profile to your VCT watchlist for a quick return.
Stage-based planning range
$100K–$1M
This is a planning range inferred from stage coverage, not a firm-disclosed check size.
Methodology: Stage bucket inferred from the rounds a fund leads or invests in.
No firm-specific check-size disclosure is recorded.
Investment stages
Leads: Not recorded
Participates: Not recorded
Sector focus
Not recorded
Geography
Paris, France; Europe plus selective international markets
Founded Not recorded
Fund size / AUM
Not recorded
A separate fund-size evidence record is not yet available.
Portfolio in our directory
None yet
Linked startup profiles
Recent tracked investment
Not recorded
No dated round explicitly links this fund.
Rounds they lead
Rounds they invest
Last verified: 2026-11-16. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.